Review



polyclonal goat anti fetuin a detection antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    R&D Systems polyclonal goat anti fetuin a detection antibody
    Polyclonal Goat Anti Fetuin A Detection Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal goat anti fetuin a detection antibody/product/R&D Systems
    Average 90 stars, based on 13 article reviews
    polyclonal goat anti fetuin a detection antibody - by Bioz Stars, 2026-03
    90/100 stars

    Images



    Similar Products

    90
    R&D Systems polyclonal goat anti fetuin a detection antibody
    Polyclonal Goat Anti Fetuin A Detection Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal goat anti fetuin a detection antibody/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    polyclonal goat anti fetuin a detection antibody - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    R&D Systems polyclonal anti-human ahsg antibodies
    Polyclonal Anti Human Ahsg Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal anti-human ahsg antibodies/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    polyclonal anti-human ahsg antibodies - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    91
    BioVendor Instruments polyclonal goat anti human fetuin a antibodies
    Stratified associations between pre-diagnostic <t>fetuin-A</t> and incident diabetes-related complications. A P for interaction with sex p = 0.18 for complications overall, p = 0.18 for microvascular and p = 0.56 for macrovascular complications. B P for interaction with baseline glucose (glucose ≥ 100 mg/dL vs glucose < 100 mg/dL) p = 0.85 for complications overall, p = 0.67 with microvascular and p = 0.31 for macrovascular complications. C P for interaction with FLI (FLI < 60 vs FLI ≥ 60) p = 0.94 for complications overall, p = 0.65 for microvascular complications. D P for interaction with baseline fasting status (fasted vs non-fasted) p = 0.36 for complications overall and p = 0.57 with microvascular complications. E P for interaction with baseline eGFR (eGFR ≥ 80 mL/min/1.73 m 2 vs < 80 mL/min/1.73 m 2 ) p = 0.10 for complications overall, p = 0.15 for microvascular complications. There were not enough macrovascular events in the subgroups with baseline eGFR < 80 mL/min/1.73 m 2 , FLI < 60 and fasted subgroup to perform the analysis. Associations were assessed by Cox proportional hazards models and are shown per one unit SD increase (0.06 g/L) in pre-diagnostic fetuin-A concentrations. Models are adjusted for age at diabetes diagnosis (underlying time scale), duration between recruitment and diabetes diagnosis, sex, education (three categories: no or in vocational training, vocational training/technical school, technical college or university), alcohol intake (six categories: < 6.1 g/day, 6.1–12.0 g/day, 12.1–24.0 g/day, 24.1–60.0 g/day, 60.1–96.0 g/day, > 96.0 g/day), smoking (four categories: never smoker, former smoker, current smoker < 20 cigarettes/day, current heavy smoker ≥ 20 cigarettes/day), physical activity (sports ≤ 4 h/week, sports > 4 h/week, biking < 2.5 h/week, biking 2.5–4.9 h/week, biking ≥ 5 h/week), body mass index, waist circumference, history of hypertension, hyperlipidemia, antihypertensive and lipid lowering medications at the time of recruitment. HR, hazard ratio; CI, confidence interval; SD, standard deviation; eGFR, estimated glomerular filtration rate; FLI, fatty liver index
    Polyclonal Goat Anti Human Fetuin A Antibodies, supplied by BioVendor Instruments, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal goat anti human fetuin a antibodies/product/BioVendor Instruments
    Average 91 stars, based on 1 article reviews
    polyclonal goat anti human fetuin a antibodies - by Bioz Stars, 2026-03
    91/100 stars
      Buy from Supplier

    91
    BioVendor Instruments human fetuin a
    Stratified associations between pre-diagnostic <t>fetuin-A</t> and incident diabetes-related complications. A P for interaction with sex p = 0.18 for complications overall, p = 0.18 for microvascular and p = 0.56 for macrovascular complications. B P for interaction with baseline glucose (glucose ≥ 100 mg/dL vs glucose < 100 mg/dL) p = 0.85 for complications overall, p = 0.67 with microvascular and p = 0.31 for macrovascular complications. C P for interaction with FLI (FLI < 60 vs FLI ≥ 60) p = 0.94 for complications overall, p = 0.65 for microvascular complications. D P for interaction with baseline fasting status (fasted vs non-fasted) p = 0.36 for complications overall and p = 0.57 with microvascular complications. E P for interaction with baseline eGFR (eGFR ≥ 80 mL/min/1.73 m 2 vs < 80 mL/min/1.73 m 2 ) p = 0.10 for complications overall, p = 0.15 for microvascular complications. There were not enough macrovascular events in the subgroups with baseline eGFR < 80 mL/min/1.73 m 2 , FLI < 60 and fasted subgroup to perform the analysis. Associations were assessed by Cox proportional hazards models and are shown per one unit SD increase (0.06 g/L) in pre-diagnostic fetuin-A concentrations. Models are adjusted for age at diabetes diagnosis (underlying time scale), duration between recruitment and diabetes diagnosis, sex, education (three categories: no or in vocational training, vocational training/technical school, technical college or university), alcohol intake (six categories: < 6.1 g/day, 6.1–12.0 g/day, 12.1–24.0 g/day, 24.1–60.0 g/day, 60.1–96.0 g/day, > 96.0 g/day), smoking (four categories: never smoker, former smoker, current smoker < 20 cigarettes/day, current heavy smoker ≥ 20 cigarettes/day), physical activity (sports ≤ 4 h/week, sports > 4 h/week, biking < 2.5 h/week, biking 2.5–4.9 h/week, biking ≥ 5 h/week), body mass index, waist circumference, history of hypertension, hyperlipidemia, antihypertensive and lipid lowering medications at the time of recruitment. HR, hazard ratio; CI, confidence interval; SD, standard deviation; eGFR, estimated glomerular filtration rate; FLI, fatty liver index
    Human Fetuin A, supplied by BioVendor Instruments, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human fetuin a/product/BioVendor Instruments
    Average 91 stars, based on 1 article reviews
    human fetuin a - by Bioz Stars, 2026-03
    91/100 stars
      Buy from Supplier

    Image Search Results


    Stratified associations between pre-diagnostic fetuin-A and incident diabetes-related complications. A P for interaction with sex p = 0.18 for complications overall, p = 0.18 for microvascular and p = 0.56 for macrovascular complications. B P for interaction with baseline glucose (glucose ≥ 100 mg/dL vs glucose < 100 mg/dL) p = 0.85 for complications overall, p = 0.67 with microvascular and p = 0.31 for macrovascular complications. C P for interaction with FLI (FLI < 60 vs FLI ≥ 60) p = 0.94 for complications overall, p = 0.65 for microvascular complications. D P for interaction with baseline fasting status (fasted vs non-fasted) p = 0.36 for complications overall and p = 0.57 with microvascular complications. E P for interaction with baseline eGFR (eGFR ≥ 80 mL/min/1.73 m 2 vs < 80 mL/min/1.73 m 2 ) p = 0.10 for complications overall, p = 0.15 for microvascular complications. There were not enough macrovascular events in the subgroups with baseline eGFR < 80 mL/min/1.73 m 2 , FLI < 60 and fasted subgroup to perform the analysis. Associations were assessed by Cox proportional hazards models and are shown per one unit SD increase (0.06 g/L) in pre-diagnostic fetuin-A concentrations. Models are adjusted for age at diabetes diagnosis (underlying time scale), duration between recruitment and diabetes diagnosis, sex, education (three categories: no or in vocational training, vocational training/technical school, technical college or university), alcohol intake (six categories: < 6.1 g/day, 6.1–12.0 g/day, 12.1–24.0 g/day, 24.1–60.0 g/day, 60.1–96.0 g/day, > 96.0 g/day), smoking (four categories: never smoker, former smoker, current smoker < 20 cigarettes/day, current heavy smoker ≥ 20 cigarettes/day), physical activity (sports ≤ 4 h/week, sports > 4 h/week, biking < 2.5 h/week, biking 2.5–4.9 h/week, biking ≥ 5 h/week), body mass index, waist circumference, history of hypertension, hyperlipidemia, antihypertensive and lipid lowering medications at the time of recruitment. HR, hazard ratio; CI, confidence interval; SD, standard deviation; eGFR, estimated glomerular filtration rate; FLI, fatty liver index

    Journal: Cardiovascular Diabetology

    Article Title: Fetuin-A and risk of diabetes-related vascular complications: a prospective study

    doi: 10.1186/s12933-021-01439-8

    Figure Lengend Snippet: Stratified associations between pre-diagnostic fetuin-A and incident diabetes-related complications. A P for interaction with sex p = 0.18 for complications overall, p = 0.18 for microvascular and p = 0.56 for macrovascular complications. B P for interaction with baseline glucose (glucose ≥ 100 mg/dL vs glucose < 100 mg/dL) p = 0.85 for complications overall, p = 0.67 with microvascular and p = 0.31 for macrovascular complications. C P for interaction with FLI (FLI < 60 vs FLI ≥ 60) p = 0.94 for complications overall, p = 0.65 for microvascular complications. D P for interaction with baseline fasting status (fasted vs non-fasted) p = 0.36 for complications overall and p = 0.57 with microvascular complications. E P for interaction with baseline eGFR (eGFR ≥ 80 mL/min/1.73 m 2 vs < 80 mL/min/1.73 m 2 ) p = 0.10 for complications overall, p = 0.15 for microvascular complications. There were not enough macrovascular events in the subgroups with baseline eGFR < 80 mL/min/1.73 m 2 , FLI < 60 and fasted subgroup to perform the analysis. Associations were assessed by Cox proportional hazards models and are shown per one unit SD increase (0.06 g/L) in pre-diagnostic fetuin-A concentrations. Models are adjusted for age at diabetes diagnosis (underlying time scale), duration between recruitment and diabetes diagnosis, sex, education (three categories: no or in vocational training, vocational training/technical school, technical college or university), alcohol intake (six categories: < 6.1 g/day, 6.1–12.0 g/day, 12.1–24.0 g/day, 24.1–60.0 g/day, 60.1–96.0 g/day, > 96.0 g/day), smoking (four categories: never smoker, former smoker, current smoker < 20 cigarettes/day, current heavy smoker ≥ 20 cigarettes/day), physical activity (sports ≤ 4 h/week, sports > 4 h/week, biking < 2.5 h/week, biking 2.5–4.9 h/week, biking ≥ 5 h/week), body mass index, waist circumference, history of hypertension, hyperlipidemia, antihypertensive and lipid lowering medications at the time of recruitment. HR, hazard ratio; CI, confidence interval; SD, standard deviation; eGFR, estimated glomerular filtration rate; FLI, fatty liver index

    Article Snippet: Fetuin-A was determined with an immunoturbidimetric method with specific polyclonal goat anti-human fetuin-A antibodies to human fetuin-A (BioVendor Laboratory Medicine, Modreci, Czech Republic).

    Techniques: Diagnostic Assay, Activity Assay, Standard Deviation, Filtration

    Stratified associations between pre-diagnostic fetuin-A and incident diabetes-related complications. A P for interaction with sex p = 0.18 for complications overall, p = 0.18 for microvascular and p = 0.56 for macrovascular complications. B P for interaction with baseline glucose (glucose ≥ 100 mg/dL vs glucose < 100 mg/dL) p = 0.85 for complications overall, p = 0.67 with microvascular and p = 0.31 for macrovascular complications. C P for interaction with FLI (FLI < 60 vs FLI ≥ 60) p = 0.94 for complications overall, p = 0.65 for microvascular complications. D P for interaction with baseline fasting status (fasted vs non-fasted) p = 0.36 for complications overall and p = 0.57 with microvascular complications. E P for interaction with baseline eGFR (eGFR ≥ 80 mL/min/1.73 m 2 vs < 80 mL/min/1.73 m 2 ) p = 0.10 for complications overall, p = 0.15 for microvascular complications. There were not enough macrovascular events in the subgroups with baseline eGFR < 80 mL/min/1.73 m 2 , FLI < 60 and fasted subgroup to perform the analysis. Associations were assessed by Cox proportional hazards models and are shown per one unit SD increase (0.06 g/L) in pre-diagnostic fetuin-A concentrations. Models are adjusted for age at diabetes diagnosis (underlying time scale), duration between recruitment and diabetes diagnosis, sex, education (three categories: no or in vocational training, vocational training/technical school, technical college or university), alcohol intake (six categories: < 6.1 g/day, 6.1–12.0 g/day, 12.1–24.0 g/day, 24.1–60.0 g/day, 60.1–96.0 g/day, > 96.0 g/day), smoking (four categories: never smoker, former smoker, current smoker < 20 cigarettes/day, current heavy smoker ≥ 20 cigarettes/day), physical activity (sports ≤ 4 h/week, sports > 4 h/week, biking < 2.5 h/week, biking 2.5–4.9 h/week, biking ≥ 5 h/week), body mass index, waist circumference, history of hypertension, hyperlipidemia, antihypertensive and lipid lowering medications at the time of recruitment. HR, hazard ratio; CI, confidence interval; SD, standard deviation; eGFR, estimated glomerular filtration rate; FLI, fatty liver index

    Journal: Cardiovascular Diabetology

    Article Title: Fetuin-A and risk of diabetes-related vascular complications: a prospective study

    doi: 10.1186/s12933-021-01439-8

    Figure Lengend Snippet: Stratified associations between pre-diagnostic fetuin-A and incident diabetes-related complications. A P for interaction with sex p = 0.18 for complications overall, p = 0.18 for microvascular and p = 0.56 for macrovascular complications. B P for interaction with baseline glucose (glucose ≥ 100 mg/dL vs glucose < 100 mg/dL) p = 0.85 for complications overall, p = 0.67 with microvascular and p = 0.31 for macrovascular complications. C P for interaction with FLI (FLI < 60 vs FLI ≥ 60) p = 0.94 for complications overall, p = 0.65 for microvascular complications. D P for interaction with baseline fasting status (fasted vs non-fasted) p = 0.36 for complications overall and p = 0.57 with microvascular complications. E P for interaction with baseline eGFR (eGFR ≥ 80 mL/min/1.73 m 2 vs < 80 mL/min/1.73 m 2 ) p = 0.10 for complications overall, p = 0.15 for microvascular complications. There were not enough macrovascular events in the subgroups with baseline eGFR < 80 mL/min/1.73 m 2 , FLI < 60 and fasted subgroup to perform the analysis. Associations were assessed by Cox proportional hazards models and are shown per one unit SD increase (0.06 g/L) in pre-diagnostic fetuin-A concentrations. Models are adjusted for age at diabetes diagnosis (underlying time scale), duration between recruitment and diabetes diagnosis, sex, education (three categories: no or in vocational training, vocational training/technical school, technical college or university), alcohol intake (six categories: < 6.1 g/day, 6.1–12.0 g/day, 12.1–24.0 g/day, 24.1–60.0 g/day, 60.1–96.0 g/day, > 96.0 g/day), smoking (four categories: never smoker, former smoker, current smoker < 20 cigarettes/day, current heavy smoker ≥ 20 cigarettes/day), physical activity (sports ≤ 4 h/week, sports > 4 h/week, biking < 2.5 h/week, biking 2.5–4.9 h/week, biking ≥ 5 h/week), body mass index, waist circumference, history of hypertension, hyperlipidemia, antihypertensive and lipid lowering medications at the time of recruitment. HR, hazard ratio; CI, confidence interval; SD, standard deviation; eGFR, estimated glomerular filtration rate; FLI, fatty liver index

    Article Snippet: Fetuin-A was determined with an immunoturbidimetric method with specific polyclonal goat anti-human fetuin-A antibodies to human fetuin-A (BioVendor Laboratory Medicine, Modreci, Czech Republic).

    Techniques: Diagnostic Assay, Activity Assay, Standard Deviation, Filtration